Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen's SMA Ambitions Run Up Against A New Deep-Pocketed Rival

Apr 09 2018

• By Jessica Merrill

Related Content

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Apr 09 2018

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Dec 28 2016

J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly

Jan 09 2018

Related Companies

Novartis AG

AveXis, Inc.

Ionis Pharmaceuticals, Inc.

Additional Topics

Deals Rare Diseases Commercial Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window